SNAP-8 (Acetyl Octapeptide-3) vs SS-31
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
SNAP-8 (Acetyl Octapeptide-3)
8-amino acid cosmetic peptide active (Acetyl Octapeptide-3) that competes with SNARE complex proteins to reduce neuromuscular signal transmission in facial expression muscles. An extended, more potent version of Argireline (Acetyl Hexapeptide-3). Clinical studies show 26–63% reduction in expression wrinkle depth with twice-daily application, positioning it as a topical botulinum toxin alternative.
Full profileSS-31
SS-31 (Elamipretide) is a mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane, protecting cardiolipin and restoring mitochondrial function. It is being studied for heart failure, aging, and metabolic disease. One of the most exciting longevity-adjacent peptides in current research.
Full profile| SNAP-8 (Acetyl Octapeptide-3) | SS-31 | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | Leuphasyl, Acetyl Octapeptide-3, SNAP-8 peptide, Argireline extension, Acetyl Glutamyl Heptapeptide-3 | Elamipretide, MTP-131, Bendavia, Szeto-Schiller peptide 31 |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 1%–10% %, twice daily topical application | 1mg–10mg mg, daily or every other day |
| Administration | Topical (serum/cream) | Subcutaneous injection, Intravenous (clinical trials) |
| Key side effects | Very well-tolerated, Rare mild skin irritation or redness, No systemic absorption at cosmetic concentrations, No paralysis risk (partial SNARE competition only) | Injection site reactions, Nausea (rare), Generally well-tolerated in clinical trial populations |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: SNAP-8 (Acetyl Octapeptide-3) is research-stage, while SS-31 is investigational (in trials).
- Administration: SNAP-8 (Acetyl Octapeptide-3) — Topical (serum/cream); SS-31 — Subcutaneous injection, Intravenous (clinical trials).
- Dosing units differ: SNAP-8 (Acetyl Octapeptide-3) is dosed in %, SS-31 in mg — they operate at different scales.
- Frequency: SNAP-8 (Acetyl Octapeptide-3) is typically twice daily topical application; SS-31 is daily or every other day.
How each works
SNAP-8 (Acetyl Octapeptide-3)
SNAP-8 mimics the N-terminal domain of SNAP-25, competing for SNARE complex assembly required for acetylcholine vesicle fusion at the neuromuscular junction. This partial inhibition reduces muscle contraction intensity without complete paralysis. Clinical studies demonstrate statistically significant reductions in crow's feet and forehead line depth after 28 days of use at 5–10% concentration.
SS-31
SS-31 selectively accumulates in mitochondria and binds cardiolipin — a phospholipid critical for the electron transport chain. By stabilizing cardiolipin, SS-31 restores ATP production, reduces reactive oxygen species (ROS), and prevents mitochondrial permeability transition. Animal studies show dramatic reversal of mitochondrial dysfunction in aged tissues.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.